Clinical Trial Detail

NCT ID NCT04445844
Title INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Rutgers, The State University of New Jersey
Indications

triple-receptor negative breast cancer

Therapies

Pelareorep + Retifanlimab

Age Groups: senior adult

No variant requirements are available.